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Abstract
Background: Nitric oxide synthase 2 (NOS2) contributes to neural death in some settings, but
its role in glaucoma remains controversial. NOS2 is implicated in retinal ganglion cell degeneration
in a rat glaucoma model in which intraocular pressure (IOP) is experimentally elevated by blood
vessel cauterization, but not in a rat glaucoma model where IOP was elevated by injection of
hypertonic saline. To test the importance of NOS2 for an inherited glaucoma, in this study we both
genetically and pharmacologically decreased NOS2 activity in the DBA/2J mouse glaucoma model.
Methods: The expression of Nos2 in the optic nerve head was analyzed at both the RNA and
protein levels at different stages of disease pathogenesis. To test the involvement of Nos2 in
glaucomatous neurodegeneration, a null allele of Nos2 was backcrossed into DBA/2J mice and the
incidence and severity of glaucoma was assessed in mice of each Nos2 genotype. Additionally, DBA/
2J mice were treated with the NOS2 inhibitor aminoguanidine and the disease compared to
untreated mice.
Results: Optic nerve head Nos2 RNA levels varied and increased during moderate but decreased
at early and severe stages of disease. Despite the presence of a few NOS2 positive cells in the optic
nerve head, NOS2 protein was not substantially increased during the glaucoma. Genetic deficiency
of Nos2 or aminoguanidine treatment did not alter the IOP profile of DBA/2J mice. Additionally,
neither Nos2 deficiency nor aminoguanidine had any detectable affect on the glaucomatous optic
nerve damage.
Conclusion: Glaucomatous neurodegeneration in DBA/2J mice does not require NOS2 activity.
Further experiments involving various models are needed to assess the general importance of Nos2
in glaucoma.
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Background
Glaucoma affects the vision of approximately 70 million
people [1,2]. Optic nerve head excavation and degenera-
tion of retinal ganglion cells (RGCs)are unifying charac-
teristics of glaucoma. The causes of glaucoma are diverse
and complex [3]. Many risk factors are known for glau-
coma [3-5], with elevated intraocular pressure (IOP)
being prominent [4-9]. IOP can be pharmacologically
lowered, which in some cases can inhibit the develop-
ment and progression of glaucoma [10-12]. However, in a
significant number of cases, decreasing IOP does not pre-
vent glaucoma progression. Identifying and targeting the
mechanisms of RGC degeneration could help to protect
the vision of more patients. Unfortunately, the molecular
mechanisms of glaucoma are not well understood, and
currently no therapies that target the neurodegeneration
are commonly employed in clinical practice.
Nitric oxide has different roles in the central nervous sys-
tem. Nitric oxide synthase 2 (Nos2; or inducible Nos, iNos)
can be induced in response to a variety of external signals.
In some settings, NOS2 activity plays an important role in
inducing neurodegeneration [13,14]. Nitric oxide produc-
tion, particularly through NOS2, has been implicated in
ischemia-induced death in the retina [15-18]. The ability
of a NOS2 inhibitor to protect RGCs from ischemia led to
the suggestion that NOS2 inhibition may be protective in
glaucoma [18]. The possibility that NOS2 inhibition
could be neuroprotective in glaucoma was strengthened
by a report showing that NOS2 inhibition delays RGC
degeneration after axotomy [19].
Several lines of evidence point to a possible role for NOS2
in mediating glaucomatous neurodegeneration. In glau-
coma patients, NOS2 expression was found to be up-reg-
ulated in optic nerve head glia [20-22]. The optic nerve
head is believed to be an important site of damage in glau-
coma [23-30]. In addition, human optic nerve head astro-
cytes can be induced to express NOS2 by either cytokines
[22] or increased hydrostatic pressure [31]. NOS2 is
induced in astrocytes of the optic nerve head in eyes of rats
that have had intraocular pressure artificially increased by
cauterization of the extraocular veins [32]. In the same rat
model of glaucoma, pharmacological inhibition of NOS2
by aminoguanidine or L-N(6)-(1-iminoethyl)lysine 5-
tetrazole amide reduced the number of RGCs that died
[33,34].
The general importance of NOS2 in glaucoma was
recently questioned by studies that do not support a role
for NOS2 in another model of glaucoma [35,36]. Thus,
the general importance of NOS2 induction for glaucoma
is not certain. Considering these conflicting results from
different induced rat models of glaucoma, it is important
to further test the potential involvement of NOS2 in an
inherited mouse model of glaucoma.
The DBA/2J mouse develops an inherited glaucoma with
IOP elevation that is secondary to a pigment dispersing
iris disease. DBA/2J glaucoma is similar to human glauco-
mas in that it is age-related and the pressure elevation is
natural and variable [37-41]. The DBA/2 mouse has
become one of the most widely used glaucoma models.
The pressure elevation often leads to massive RGC loss,
with the majority of eyes losing greater than 90% of their
RGCs [40,42]. Reported differences in the timing and
nature of neuron death in DBA/2 substrains point to a
complex disease process that is affected by environmental
as well as genetic differences between colonies of mice
[40]. In our well characterized colony of DBA/2J mice,
RGCs are specifically vulnerable to the glaucoma [28]. The
pattern of RGC death supports involvement of axon
injury in the optic nerve of DBA/2J mice [28,43] as well as
in a closely related strain, DBA/2NNia [44]. In fact,
detailed studies of the optic nerve support early injury of
RGC axons as a key pathologic feature of DBA/2 glauco-
mas [45,46], with experimental evidence for an insult(s)
damaging axons within the optic nerve head [45]. Consid-
ering the complex disease etiology, the specific vulnerabil-
ity of RGCs, the characteristic pattern of RGC death and
the early axon damage in the optic nerve head, DBA/2J
glaucoma has important similarities to human glaucoma.
For these reasons, we used DBA/2J mice in the current
study. We used both genetic ablation and pharmacologi-
cal inhibition of NOS2activity to test the involvement of
NOS2 in glaucomatous damage to the optic nerve and ret-
ina in this inherited glaucoma model.
Results
NOS2 expression during DBA/2J glaucoma
In some [19-22,32] but not all studies [35,36,47],
increased expression of Nos2  is reported in glaucoma
patients and rat models of glaucoma. To determine the
temporal and spatial expression pattern of Nos2 in DBA/
2J mice, we examined RNA and protein levels in the optic
nerve head at different stages of glaucoma. The optic nerve
head extending from the vitreal surface to approximately
the non-myelinated-myelin junction of the optic nerve
was dissected and used for RNA preparation. There was a
modest increase of Nos2 RNA by quantitative real time
PCR analysis in eyes with moderate axon damage, but
Nos2 levels appeared to be lower in eyes with early or
severe damage (Fig. 1A). Immunohistochemical analysis
of sagittal sections did not detect NOS2 protein in either
the retina or optic nerve head in the majority of eyes at
each stage of disease. As a positive control, kidney sections
from mice treated with lipopolysaccahride (LPS) were
immunoreacted with the NOS2 antibody and NOS2 pos-
itive cells were detected (Fig. 1B). Rare cells that wereBMC Neuroscience 2007, 8:108 http://www.biomedcentral.com/1471-2202/8/108
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NOS2 positive were identified in the optic nerve head of
two severely affected eyes (Fig. 1C). Although these
expression studies provided no clear association between
NOS2 and glaucoma, NOS2 is a powerful modulator of
cell functions that may be transiently expressed by single
cells. Therefore, we continued to test the role of NOS2 in
NOS2 expression during glaucoma progression Figure 1
NOS2 expression during glaucoma progression. (A) Optic nerve head Nos2 RNA expression. Relative expression levels 
of Nos2 at different stages of glaucoma were determined using ΔCT ratios (see Methods). 'Control' eyes from 4 months old 
DBA/2J mice were considered to be pre-glaucomatous and showed no axon damage. 'Sample' eyes from 10.5 months old DBA/
2J mice were assessed for glaucomatous axon damage and grouped into the no or early, moderate or severe stages of damage 
(see Methods). Values given are relative to pre-glaucoma controls. Nos2 expression was variable within each disease group 
(indicated by the SEM bars). Overall it decreased comparing pre-glaucoma with no or early glaucoma and increased modestly in 
eyes with moderate glaucoma (p < 0.05). (B) NOS2 protein localization in LPS-treated kidney (above) and no primary control 
(below). The NOS2 antibody shows strong and specific NOS2 staining (Red) in LPS-treated kidneys, with no non-specific bind-
ing of the secondary antibody. (C) NOS2 protein localization in the optic nerve heads of 10.5 months old DBA/2J mice, with 
the lower panels showing higher magnification of the boxed regions. There was no obvious correlation between NOS2 locali-
zation and glaucoma progression, although rare NOS2 positive cells were seen in eyes with severe glaucoma (arrow). All sec-
tions were processed, stained and imaged under identical conditions. The images shown here are representative of three 
different sections from three different eyes with the three different stages of glaucoma. Bars = 75 μm.BMC Neuroscience 2007, 8:108 http://www.biomedcentral.com/1471-2202/8/108
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this glaucoma by both genetically and pharmacologically
inhibiting its function.
NOS2 deficiency does not alter the IOP profile of DBA/2J 
mice
To investigate the involvement of Nos2, a null allele of
Nos2  (Nos2tm1Lau [Nos2tm1Lau; [48]]) was backcrossed
into the DBA/2J strain for greater than 13 generations. The
genetic removal of Nos2 ensures that there is no enzymatic
activity throughout life. Glaucoma in DBA/2J mice is the
result of elevated IOP that is secondary to an iris disease.
Preventing or lessening the iris disease alleviates IOP ele-
vation and prevents the subsequent neurodegeneration
[38,49,50]. Therefore, it is necessary to determine whether
Nos2 genotype altered the iris disease or IOP profile. Slit
lamp examination at various time points throughout the
experiment showed that Nos2 genotype had no affect on
the age of onset, progression, or severity of the iris disease
(data not shown). Importantly, Nos2 genotype did not
alter IOP in either young or aged mice (Fig. 2), and mice
of all genotypes had a glaucomatous IOP elevation at 10–
11 months of age (Fig. 2, P < 0.001, ANOVA, for all com-
parisons compared to young mice).
NOS2 deficiency does not prevent glaucomatous 
neurodegeneration
Some optic nerves from DBA/2J mice begin to show signs
of glaucomatous neurodegeneration at 9 months of age
[40]. The incidence and severity of glaucoma then
increases rapidly over the next months, but not all mice
develop glaucomatous nerve damage. Complete defi-
ciency of NOS2 did not prevent homozygous mutant
mice from developing severe glaucoma (Fig. 3C, D, E),
showing that NOS2 is not required for glaucomatous
axon degeneration in the optic nerve. Additionally, NOS2
deficiency did not lessen the amount of glaucomatous
optic nerve degeneration in mice that were 10–12 months
of age (Fig. 3E).
Although NOS2 deficiency did not affect axon degenera-
tion, it is a formal possibility that it may affect apoptosis
of the RGC somata. We have previously shown that BAX
deficiency (BAX is a potent regulator of apoptosis) pre-
vents somal apoptosis even when almost all RGC axons
have degenerated in the optic nerve [42]. To assess if
NOS2 deficiency protects RGC somata, even though it has
no affect on their axons, we counted RGC layer cells for
eyes whose nerves demonstrated different degrees of axon
damage. Nos2 genotype had no affect on the number of
RGC layer cells in mice with either 'no or early' or severe
glaucomatous optic nerve damage (Fig. 3F). Thus, NOS2
deficiency does not differentially protect the RGC somata.
Overall, our genetic studies detected no beneficial affect of
completely removing NOS2 activity in glaucomatous
DBA/2J mice.
Aminoguanidine Treatment
The lack of detectable protective affect of genetically ablat-
ing NOS2 contrasts with the report of Neufeld and col-
leagues [51], who found that the NOS2 inhibitor
aminoguanidine was neuroprotective in a rat model with
induced IOP elevation. The outcome of these genetic and
pharmacological studies may differ for a variety of rea-
sons, including the possibility that the chemical inhibitor
is not completely specific and has unknown off-target
effects that may affect outcome. To better understand our
findings in light of these reports, and to assess whether
aminoguanidine has off-target effects that protect against
glaucoma by a mechanism that is independent of NOS2,
we tested the ability of aminoguanidine treatment to alle-
viate the glaucoma of DBA/2J mice.
Starting at either 3 or 5 months of age (2 different experi-
ments), aminoguanidine (Ag) was administered in drink-
ing water (1 mg/ml). Water consumption was measured
for 50 Ag-treated and 50 non-treated mice, to determine
the dose of Ag the mice received and whether Ag in the
drinking water affected water consumption. Aminoguani-
dine did not affect the amount of water mice consumed
NOS2 deficiency does not alter IOP Figure 2
NOS2 deficiency does not alter IOP. The IOP distribu-
tions of mice of each genotype overlap extensively. The 
boxes show the upper and lower quartiles and the bars show 
the extremes including outliers. The centerline of each dia-
mond is the mean with the upper and lower points of each 
diamond representing the 95% confidence intervals of the 
mean. Mean ± s.e.m in mm Hg, number of eyes examined; 3.5 
months, Nos+/+ 12.6 ± 0.24, 18; Nos+/- 11.9 ± 0.30, 19; Nos-/- 
12.2 ± 0.19, 19; P value for all comparisons > 0.08; 10–11 
months, Nos+/+ 21.9 ± 0.87, 39; Nos+/- 21.0 ± 0.95, 32; Nos-/- 
23.6 ± 1.3, 30, P value for all comparisons >0.09.BMC Neuroscience 2007, 8:108 http://www.biomedcentral.com/1471-2202/8/108
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NOS2 deficiency does not alter glaucomatous neurodegeneration Figure 3
NOS2 deficiency does not alter glaucomatous neurodegeneration. (A, B) There were no gross anatomical differ-
ences between young Nos2+/+ (A) and Nos2-/- (B) nerves. (C) Eventually 80% of the optic nerves of DBA/2J mice develop 
severe optic nerve degeneration (Nos2+/+). (D) The complete absence of NOS2 did not prevent glaucomatous neurodegenera-
tion as many Nos2-/- nerves had severe axonal damage. (E) Nos2 genotype had no effect on the distribution of nerve damage. 
Numbers of nerves by age, genotype and disease state were: (given as total number analyzed, genotype, number of that geno-
type with mild, moderate, severe glaucoma) 3.5 months 6 Nos2+/+ 6,0,0; 7 Nos2+/- 7,0,0;11 Nos2-/- 11,0,0; 10–12 months 53 
Nos2+/+ 23,3,27; 53 Nos2+/- 21,9,23; 56 Nos2-/- 17,3,36 (P value for all comparisons > 0.3). F) Average counts of RGC layer neu-
rons from Nos2 mice of each genotype with either severe glaucomatous damage or no detectable glaucomatous damage (total 
number of cells of the 8 fields counted per retina; see methods). Nos2 genotype conferred no differential protective effect to 
RGCs in eyes with different degrees of axon loss. RGCs comprise 45–50% of cells in the RGC layer [71] and so almost all 
RGCs were lost in mice with severe axon loss independent of Nos2 genotype. Percentage of surviving cells; Nos2+/+, 54.4% ± 
1.5; Nos2+/-, 54.6% ± 1.5; Nos2-/-, 58.0% ± 2.5; P values for all comparisons > 0.28. Number of retinal flat mounts counted, 
(given as genotype, mild, severe) Nos2+/+ 9, 7; Nos2+/- 12, 8; Nos2-/- 8, 13. Bar = 100 μm.BMC Neuroscience 2007, 8:108 http://www.biomedcentral.com/1471-2202/8/108
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(non-treated mice 4.0 ± 0.3 ml/day and Ag-treated 3.9 ±
0.2 ml/day; P = 0.736) nor did it affect their body weight
even after being on the drug for 6 months (average g ±
SEM, number of mice; control, 35.2 ± 1.0, 50; Ag-treated,
35.4 ± 0.9, 51; p = 0.89). This level of water consumption
resulted in a calculated dose of 110 mg/kg/day. This dose
is similar to that achieved by Neufeld and colleagues in
their aged rats (mean rat body weight 0.575 kg, daily con-
sumption 60 mg, dose 104 mg/kg/day).
Aminoguanidine treatment does not alter IOP
Ag-treatment did not change the time course or the sever-
ity of the iris disease (data not shown). We first checked
for any affect of Ag-treatment on IOP using young pre-
glaucomatous DBA/2J mice. The IOP of young mice was
not altered by Ag-treatment from 2 to 3.5 months of age.
Similarly long-term Ag-treatment had no affect on IOP
when assessed at 10 to 11 months, key ages of elevation in
both sexes [39,40]. The IOPs of treated mice were signifi-
cantly elevated compared to young mice (P < 0.001).
Importantly, Ag-treatment did not alter the average IOP or
the population distribution (Fig. 4A). The lack of effect of
Ag-treatment on IOP is consistent with previous studies
[35,51].
Aminoguanidine treatment is not effective at preventing 
glaucomatous neurodegeneration
When treatment was started at 5 months of age using mice
housed at The Jackson Laboratory, Ag-treatment did not
alter the distribution of nerve damage at either 10 or 11.5
months (Fig. 4B; p > 0.2 for both ages). In fact, many mice
developed severe glaucoma despite Ag-treatment. This
lack of protection was confirmed with a second experi-
ment using large cohorts of mice. These mice were housed
and treated at Alcon Laboratories. The Ag treatment was
the same except that it commenced at 3 months of age. For
these mice, glaucomatous optic nerve damage was
assessed at 9, 10 and 11 months of age (Fig. 4C). At no
time point did Ag protect from degeneration, and at 9
months it tended to exacerbate the disease (P = 0.04).
Interestingly, the damage was more severe in the second
experiment. This fits with the variability of disease
between different reports from different institutions and
suggests that environmental factors alter disease progres-
sion in DBA/2J mice [40,44,52]. Overall, our combina-
tion of genetic and pharmacologic experiments provides
no evidence for a role of NOS2 in this model of glaucoma.
Discussion
Deciphering the mechanisms responsible for RGC dys-
function and demise in glaucoma is expected to lead to
new neuroprotective treatments that will help to preserve
the vision of more patients. NOS2 can be induced in nerv-
ous system microglia and astrocytes during disease, and
NOS can act as an important mediator of neural cell dam-
age and death [13,14]. NOS2 was reported to be induced
in optic nerve glia during glaucoma, and involved in glau-
comatous damage to the retina in a rat model of glaucoma
[20-22,33,51]. Here we tested the involvement of NOS2
in glaucomatous neurodegeneration using the inherited
DBA/2J model of glaucoma. There were modest changes
in optic nerve head Nos2 RNA expression during the vari-
ous stages of disease progression. Occasionally, NOS2
protein was detected in optic nerve cells with advanced
glaucoma but not in unaffected optic nerves. However,
neither the complete genetic ablation nor the treatment
with an inhibitor of NOS2 had any affect on the severity
or incidence of this glaucoma. Although our studies have
not assessed if other nitric oxide synthases could have
compensated for the absence of NOS2, as has been sug-
gested in other systems [53], our results do not support a
damaging role of NOS2 in this mouse model of glau-
coma. We clearly demonstrate that glaucoma can manifest
even when NOS2 is completely absent.
In contrast to our results, Neufeld and colleagues have
proposed an important role for NOS2 in glaucoma and
suggested its inhibition as a treatment [21,22,31-
34,51,54-56]. These studies have provided a variety of
data supporting a role for NOS2 in glaucomatous neuro-
degeneration. They have shown that NOS2 is expressed in
the optic nerve in human glaucoma patients [20-22] and
in a rat model of ocular hypertension [32]. NOS2 expres-
sion can be induced by increased hydrostatic pressure in
cultured human astrocytes derived from human optic
nerve heads [31]. Most intriguingly, using a rat model
where IOP is artificially elevated by cauterization of
extraocular veins, Neufeld and colleagues have shown
that pharmacological inhibition of NOS2 could lessen
glaucomatous RGC death [33,51].
Recently, Pang and colleagues [35] did not find evidence
for a role of NOS2 in glaucomatous neurodegeneration.
They induced elevated IOP in rats by injection of hyper-
tonic saline into episcleral veins [57]. No significant
increase in NOS2 expression (at the protein or message
level) was found in optic nerve head cells due to ocular
hypertension. Furthermore, they found no evidence for
increased NOS2 in transected rat optic nerve heads or in
optic nerve heads from glaucoma patients. Aminoguani-
dine treatment had no affect on glaucomatous damage in
the rats. Also using episcleral injection of hypertonic
saline in rats to induce elevated IOP, Kasmala and col-
leagues [36] found that another inhibitor of NOS2, L-
N(6)-(1-iminoethyl)lysine 5-tetrazole (which has been
shown to be protective in the vessel cauterization glau-
coma model [33]) did not protect RGCs from death
induced by elevated intraocular pressure.BMC Neuroscience 2007, 8:108 http://www.biomedcentral.com/1471-2202/8/108
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Aminoguanidine treatment does not alter IOP or glaucomatous neurodegeneration Figure 4
Aminoguanidine treatment does not alter IOP or glaucomatous neurodegeneration. (A) Ag-treatment did not 
affect the pre-glaucomatous IOP of DBA/2J mice (3.5 months: average mmHg ± s.e.m., number of eyes examined; control 11.8 
± 0.2, 19; Ag-treated 11.7 ± 0.2, 23; P = 0.76). Ag-treatment did not affect the ocular hypertension during the key window in 
disease progression, between 10 and 11 months (control, 18.2 ± 1.0, 31; Ag-treatment, 16.6 ± 1.3, 30; P = 0.334). (B) Ag-treat-
ment from 5 months of age does not alter glaucomatous neurodegeneration (given as total number analyzed, treatment group, 
number of that treatment with mild, moderate, severe glaucoma) 10 months, 51 controls, 22,6,23; 51 Ag-treated 21,6,25; P = 
0.293; 11.5 months, 55 controls, 18,6,31; 46 Ag-treated, 16,7,23, P = 0.896. (C) Ag-treatment beginning at 3 months of age 
does not protect from glaucomatous neurodegeneration. Nine months old treated mice actually tended to have more severe 
damage (given as total number analyzed, treatment group, number of that treatment with mild, moderate, severe glaucoma) 9 
months, 42 controls, 27,7,8; 41 Ag-treated 17,6,18; P = 0.04; 10 months, 43 controls, 10,1,32; 49 Ag-treated, 6,2,41, P = 0.4; 11 
months, 43 controls, 4,3,36; 37 Ag-treated, 5,3,29, P = 0.8. The experiments shown in B and C were performed at different 
institutions (see text).BMC Neuroscience 2007, 8:108 http://www.biomedcentral.com/1471-2202/8/108
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There are multiple possible explanations for the differ-
ences in the observed role of NOS2 in glaucoma in these
studies, including differences in genetically determined
risk factors between the animals that were used. Pang and
colleagues discuss many of the possibilities [35]. Here we
limit discussion to a known difference between the stud-
ies of Neufeld and colleagues (which implicate NOS2)
and other studies (which detected no effect of NOS2).
Neufeld and colleagues cauterize extraocular veins to
induce high IOP. This approach is more traumatic to ves-
sels and surrounding tissue than the injection of hyper-
tonic saline into extraocular veins (the method used by
the other groups studying rats). The DBA/2J model is nat-
ural and does not involve experimentally-induced trauma
to vessels. The greater vascular trauma in the cauterization
model may somehow affect experimental outcome. It has
been suggested that the extraocular vein cauterization
method may induce retinal ischemia [58,59]. If true,
ischemia could contribute significantly more to RGC
death in the cauterization model than in the other mod-
els. NOS2 is clearly involved in ischemic retinopathy and
NOS2 inhibitors (including aminoguanidine) can protect
RGCs from ischemic injury in rats [16]. It will be impor-
tant to assess ischemic markers in the various models to
help determine if ischemia is more severe in the cauteriza-
tion model and if this explains the differential efficacy of
NOS2 inhibition.
Given the complexity of glaucoma, multiple different
mechanisms are likely to contribute to disease in individ-
ual patients [3,58,60]. The relative importance of specific
pathogenic mechanisms is likely to differ between indi-
vidual patients and individual eyes due to differences in
magnitude or duration of IOP elevation, environment,
lifestyle or genetic constitution. Moreover, it is possible
that different RGCs degenerate by different mechanisms
even within an individual eye, depending on differences
in protective or damaging factors in the local microenvi-
ronment. Mild or transient ischemia may contribute to
RGC death in some patients [reviewed in [61-63]]. Thus,
although we found no protective effect of NOS2 in the
inherited DBA/2J model of glaucoma, it will be important
to study the role of NOS2 in settings that have a greater
ischemic component. Both IOP and blood pressure deter-
mine ocular perfusion pressure, and decreased ocular per-
fusion pressure may contribute to glaucomatous damage
[64,65]. Thus, individuals with low blood pressure may
be at greater risk of glaucomatous damage and their glau-
coma may have a relatively strong ischemic component.
Using DBA/2J mice, our future studies will assess these
possibilities, including the potential protective role of
NOS2 in a low blood pressure setting.
Genetic studies of human glaucoma have identified glau-
coma genes and potential alleles that confer increased risk
of disease. These genetic studies will help to define key
pathologic mechanisms. One study reported a correlation
between a regulatory region of the NOS2 gene and the
development of primary open angle glaucoma [66]. How-
ever, in another study where the NOS2 gene was specifi-
cally assessed [67], NOS2 was not found to be associated
with glaucoma. Studies of large patient populations are
needed to exploit the full benefit of genetic studies for
glaucoma. Continued studies utilizing a variety of animal
models and human samples are clearly required to resolve
the complex molecular pathways that determine RGC sur-
vival and death in glaucoma.
Conclusion
NOS2 activity is not required for RGC death and associ-
ated axon degeneration in DBA/2J mice. Further studies
are required to assess the general importance of Nos2 in
glaucoma.
Methods
Animal Husbandry
All experiments were performed in compliance with the
ARVO statement for use of animals in ophthalmic and
vision research. All mice were bred at the Jackson Labora-
tory and maintained at The Jackson Laboratory or Alcon
Laboratories. The mice were fed NIH31 (6% fat) chow ad
libitum, and their water was acidified to pH 2.8 to 3.2. The
environment was kept at 21°C with a 14 hour light: 10
hour dark cycle. The colony was monitored for specific
pathogens by The Jackson Laboratory's routine surveil-
lance program. A null allele of Nos2, Nos2tm1Lau [48], was
backcrossed into DBA/2J for at least 13 generations. In the
experiments using the null allele, only female DBA/2J
mice were used. Furthermore, heterozygous by hetero-
zygous matings were used so that mice of each genotype
were littermates. Using this scheme protects from litter or
cage-dependent differences as mice of each genotypes are
housed together.
Quantitative Real Time PCR
Nos2 RNA expression levels were assessed in 25 eyes from
10.5 months old DBA/2J mice (10 no or early, 6 moderate
and 9 severe glaucoma – see optic nerve damage assess-
ment) along with 10 'control' eyes from 4.5 months DBA/
2J mice (pre-glaucoma). The front of each eye and lens
were removed and the optic nerve head region dissected
free using a sharpened 1 mm glass capillary. The ONH tis-
sue was placed in RNAlater (Qiagen) for at least 24 hours
then RNA was isolated using Microkit RNA extraction
(Qiagen). For each eye, 35 ng of RNA was used to generate
first strand cDNA using Message Sensor RT (Ambion).
Expression levels for Nos2 (using primers GTCATGGCT-
TCACGGGTCAG and CCAGGTCCCTGGCTAGTGCT)
and 3 control genes, Gstm5  (TCCTGCAGTCTGAC-
CGCTTC and GCGAGCTCTGGCTCAGCATA), Pias1BMC Neuroscience 2007, 8:108 http://www.biomedcentral.com/1471-2202/8/108
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(CATCTCTGCCAGCCACCAAC and TGGCCAT-
GGCTCTCTCTCAG) and Socs4 (ACGTCCACTGCCTTGT-
TCCA and AGCAGAGCTTCGGCTGCATA) were
determined for each eye. The 3 control genes were selected
as they had the most consistent expression among 194
tested genes, irrespective of damage level (data not
shown). Real time PCR reactions were prepared using
Quant-iT Ribogreen RNA assay kit (Invitrogen) and run
on the 7900 HT Fast Real Time PCR system (Applied Bio-
systems). For each eye, ΔCT values were calculated as
CT(Nos2) – Geometric Mean of CTs for normalizers
(Gstm5/Pias1/Socs4). The average of 'control' eyes was cal-
culated and relative expression values for each of the 'sam-
ple' eyes was calculated as ΔCT (sample)/ΔCT (pre-
glaucoma average). Finally, the average relative expression
values and standard errors of the mean for each of the no
or early, moderate and pre-glaucoma categories were cal-
culated. Significance was assessed using Chi squared anal-
ysis (JMP 6.0.3)
Immunohistochemistry
Whole eyes were immersion fixed in 4% paraformalde-
hyde in 1 × phosphate buffer for 24 hours at 4°C. Tissue
was then either immediately processed and embedded in
paraffin or was stored at 4°C in 0.4% paraformaldehyde
in phosphate buffer. 8 μm paraffin sections were cut and
processed for immunohistochemistry. NOS2 was visual-
ized using rabbit anti-NOS2 (Santa Cruz, 1:200), with
anti rabbit-Alexa 594 (Molecular Probes, 1;1000) as sec-
ondary. DAPI (Sigma) was used as a nuclear stain. Images
were captured using Metamorph imaging software (Ver-
sion 4.6, Universal Imaging, Downingtown, PA). All
images were further processed with Adobe Photoshop and
treated identically. As a positive control for NOS2, mice
were treated with lipopolysaccahride (LPS), which is
known to up-regulate NOS2 in the kidney. Eight hours
after a single intraperitoneal injection of LPS (10 mg/kg)
kidneys were harvested, processed and stained as
described for eyes.
Aminoguanidine Treatment
For mice in the aminoguanidine treatment group, 1 mg/
ml of aminoguanidine was added to their drinking water.
Treated and untreated water was changed on the same
schedule (2 times a week). Treatment began at 2 months
of age for the 3.5 months cohort and at 3 or 5 months of
age for the 9–12 months old mice. Treated and untreated
mice could not be in the same cage, but their cages were
intermixed on the same shelves in the animal room and
handled similarly. Roughly equal numbers of male and
female mice were used for the 3.5 and 10–12 months old
age groups. Significance was assessed using Chi squared
analysis (JMP 6.0.3)
Iris Disease and Intraocular Pressure Measurement
The experimenter was unaware of the genotype or treat-
ment group of the mouse at time of the examination. A
slit-lamp bio-microscope was used to track the iris disease
that is present in DBA/2J mice as previously reported
[37,39,40,68]. The microneedle method of IOP measure-
ment was used as previously described [69-71]. Ages and
sample sizes are detailed in the results. Statistical analysis
was by ANOVA.
Optic Nerve Damage Assessment
Retro-orbital optic nerves were fixed, processed, embed-
ded in plastic, and sectioned as previously reported
[40,42,72]. Sections were stained with paraphenylenedi-
amine (PPD), which stains all myelin sheaths, but differ-
entially stains the axoplasm of sick or dying axons darkly.
This method is more sensitive at detecting glaucomatous
damage than axon counting. This is because individual
damaged axons can be detected by PPD staining while
substantial axon loss is necessary to detect differences
when comparing axon counts (due to the considerable
variability in axon number from eye to eye). The 362 optic
nerves used in this study were independently determined
to have either no or early, moderate, or severe glaucoma-
tous damage by multiple masked investigators (see
below). Axon counts on randomly selected nerves with
each damage level have demonstrated that each assigned
level represents a clearly separable stage of disease
[42,73]. To assign a damage level, the investigators ana-
lyzed each nerve for the relative number of healthy and
damaged axons as well as the amount of gliosis. In nerves
with no or early glaucoma fewer than 2% of the axons are
lost or damaged. This mild level of damage is routinely
observed in aged-matched non-glaucomatous mice and
so we have previously called this damage level mild but
not considered it a definitive stage of glaucoma. Some of
these eyes must be at early stages of glaucoma that are not
detectable by these methods while others have no glau-
coma. Thus, we have reclassified this damage level as no
or early glaucoma when studying aged mice. Nerves with
no or early glaucoma have 51195 ± 934 (mean ± SEM, n
= 18) axons and are not statistically different from young
pre-glaucomatous DBA/2J nerves 52074 ± 451 (p > 0.05)
(n = 10). Moderately affected nerves have numerous sick
and degenerating axons throughout the nerve, but the
majority of axons appear healthy. Nerves with this level of
damage have typically lost approximately 30% of their
axons and on average have 31410 ± 2199 (n = 8) axons
remaining. Severe nerves have lost more than 50% of their
axons, and many severe nerves have lost the vast majority
of their axons(5454 ± 1211, n = 24). Of the 390 nerves
used in this study, the first two investigators assigned the
same damage level 87% of the time. If the two investiga-
tors did not assign the same damage level, a third masked
investigator graded the nerve. The first two investigatorsBMC Neuroscience 2007, 8:108 http://www.biomedcentral.com/1471-2202/8/108
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never differed by more than one damage level and the
damage level determined by the third investigators always
matched that of one of the first two investigators. The final
damage level was assigned by consensus (the most com-
mon damage level assigned). The nerve damage distribu-
tions of the different genotypes or treatment groups were
compared by Chi square analysis (JMP 6.0.3).
Retinal Flat Mounts
Retinal flat mounts were prepared and RGC layer cells
counted as previously described [42]. Briefly, eyes were
removed and fixed overnight at 4°C in 4% paraformalde-
hyde in 1 × phosphate buffer. After fixation eyes were
rinsed, processed and flat-mounted onto a microscope
slide with the RGC layer face up. The RGC layer was
stained with a modified Nissl stain. Eight 40× fields, con-
sisting of two fields from the periphery of each retinal
quadrant were electronically photographed and counted
(manually) using Metamorph software. The sum of all
eight fields was used for the total for each retina. Age
matched retinas with corresponding optic nerves that had
no signs of glaucomatous damage were used as controls
for the glaucomatous retinas. Significance (P < 0.05) was
determined using the student's t test.
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